FULVESTRANT
Pancreatic Cancer for Phase II
OHSU Knight Cancer InstituteSmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pancreatic Cancer for Phase II cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEUPROLIDE Novartis Pharmaceuticals | Phase 1 | CC |
Zoladex Novartis Pharmaceuticals | Phase 1 | CC |
gsk1120212 OHSU Knight Cancer Institute | Phase 1 | CC |
Ribociclib Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →